Biosimilars are generic impersonations (although not identical copies) of biotech drugs.
生物仿制制药是对生物技术制药进行的非专利仿制(尽管不是完全一致的复制)。
That is because there is an obstacle to biosimilars even more formidable than cost: lawsuits.
这是因为在生物仿制领域有一个比成本更难以克服的障碍：法律诉讼。
Samsung Group may also set up another joint venture to make biosimilars this year, Kim said.
金泰韩说，三星集团今年还会再成立一家合资公司生产生物仿制药。
Generics firms will do better with biosimilars than they have with conventional generic drugs, insists Viren Mehta, an industry expert.
工业专家维伦梅塔表示，无专利保护制药公司制造生物仿制药品将会比制造传统的无专利保护药品更有优势。
This will create more and different partnering opportunities as both Big Pharma and established biosimilars players create pipelines of compounds.
这会给大型制药公司和现有生物仿制药公司创造更多不同方式的合作机会。
The science involved in making biosimilars is much more complicated than that in making ordinary generics, says Andrew Pasternak of Bain &Company, a consultancy.
顾问公司贝恩咨询Bain合伙人安德鲁·帕斯特纳克(Andrew Pasternak)表示，与生产普通非专利药品相比，生产仿生物药品涉及的技术更加复杂。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Michael Kamarck of Merck, an American drugs firm which moved into biosimilars in 2008, thinks the barriers to entry are so great that “only a handful” of firms will be able to pull it off.
一家于2008年转向生物仿制制药的美国制药公司---默克公司认为进入生物仿制制药这个领域的障碍是如此之大以至于“只有几家”公司有能力成功进入。
He points to his firm’s aggressive entry into the nascent market for “biosimilars”, which are the generic equivalents of biotechnology drugs, as proof that firms like his need not be toothless.
他指出他的公司之所以勇于向新生市场发起冲击，是因为非专利药品和运用生物科技的药品是等效的，也为了证明像他一样的公司不是一无所能的。
Kiran Mazumdar-Shaw, head of Biocon, says the "easy substitution" that generics firms enjoy at the pharmacy does not work with complex biosimilars—which require a doctor's approval to dispense.
百康公司总裁基朗妈祖达尔-萧说非专利药品企业享受在制药业内享受的“简单取代策略”在复杂的生物仿制制药领域将不凑效了---在生物仿制制药领域，需要有医生的批准才可以进行。
Biotech drugs provide something of a hedge against this coming calamity, for two reasons. First, they are much harder to copy, so generic equivalents (called "biosimilars") will be slow in coming.
而生物技术制药可以提供抵抗这一灾难的利器，其中原因有二：第一，这些技术非常难摹仿，所以被称为“生物相似药”的普通替代品很难进入市场；
Biotech drugs provide something of a hedge against this coming calamity, for two reasons. First, they are much harder to copy, so generic equivalents (called "biosimilars") will be slow in coming.
而生物技术制药可以提供抵抗这一灾难的利器，其中原因有二：第一，这些技术非常难摹仿，所以被称为“生物相似药”的普通替代品很难进入市场；
应用推荐